NVST trades 22.7% below Wall Street's consensus target of $29.22.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NVST achieves its forward estimates and maintains a stable P/E multiple of 15.5x. This scenario reflects the blended consensus of 19 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Envista Holdings Corp (NVST) has a Wall Street consensus price target of $29.22, based on estimates from 19 covering analysts. With the stock currently trading at $23.82, this represents a potential upside of +22.7%. The company has a market capitalization of $3.88B.
Analyst price targets range from a low of $23.00 to a high of $34.00, representing a 38% spread in expectations. The median target of $29.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 8 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, NVST trades at a trailing P/E of 85.1x and forward P/E of 15.5x. The forward PEG ratio of 10.40 reflects a premium valuation. Analysts expect EPS to grow +164.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $23.16, with bear and bull scenarios of $14.59 and $30.52 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 XRAYDENTSPLY SIRONA Inc. | $2.0B | $9.78 | $13.40 | +37.0% | Hold | 6.4x | 32 |
 ALGNAlign Technology, Inc. | $10.6B | $148.17 | $205.25 | +38.5% | Buy | 13.1x | 33 |
 HSICHenry Schein, Inc. | $9.7B | $85.05 | $92.33 | +8.6% | Buy | 15.8x | 34 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 OMCLOmnicell, Inc. | $1.5B | $32.99 | $56.67 | +71.8% | Hold | 14.5x | 19 |
 ITGRInteger Holdings Corporation | $4.3B | $126.32 | $118.25 | -6.4% | Buy | 20.5x | 16 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
 ZBHZimmer Biomet Holdings, Inc. | $17.6B | $90.88 | $103.11 | +13.5% | Hold | 10.7x | 42 |
Quick answers to the most common questions about buying NVST stock.
The consensus Wall Street price target for NVST is $29.22, representing 22.7% upside from the current price of $23.82. With 19 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NVST has a consensus rating of "Hold" based on 19 Wall Street analysts. The rating breakdown is mixed, with 10 Hold ratings making up the largest segment. The consensus 12-month price target of $29.22 implies 22.7% upside from current levels.
With a forward P/E of 15.5331x, NVST trades at a relatively low valuation. The consensus target of $29.22 implies 22.7% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $34 for NVST, while the most conservative target is $23. The consensus of $29.22 represents the median expectation. Our quantitative valuation model projects a bull case target of $31 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NVST is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 10 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NVST stock forecast based on 19 Wall Street analysts shows a consensus price target of $29.22, with estimates ranging from $23 (bear case) to $34 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $23, with bear/bull scenarios of $15/$31.
Our quantitative valuation model calculates NVST's fair value at $23 (base case), with a bear case of $15 and bull case of $31. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
NVST trades at a forward P/E ratio of 15.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 85.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NVST, with a "Hold" consensus rating and $29.22 price target (22.7% upside). 8 of 19 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NVST analyst price targets range from $23 to $34, a 38% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $29.22 consensus represents the middle ground. Our model's $15-$31 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.